Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
TARRYTOWN, N.Y., Nov. 27, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the Deutsche Bank 2012 dbAccess BioFEST on Monday, December 3, 2012. The presentation is scheduled for 1:05 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page. An archived version of the presentation will be available for 30 days.
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.
SOURCE Regeneron Pharmaceuticals, Inc.
More by this Source
Robert A. Ingram Elected to Regeneron Board of Directors
Apr 04, 2014, 16:00 ET
Regeneron Announces Initiative for STEM Education in Hudson Valley
Apr 03, 2014, 16:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.